沐舒坦氧驱动雾化吸入治疗小儿支气管肺炎46例临床效果评价  

Clinical Evaluation of 46 Cases of Children with Bronchial Pneumonia Treated by Mucosolvan-driven Aerosol

作　　者：方淑颖 王丽红[1] FANG Shu-ying;WANG Li-hong(Department of Pediatrics,Danyang People's Hospital,Danyang,Jiangsu Province,212300 China)

机构地区：[1]丹阳市人民医院儿科

出　　处：《中外医疗》2019年第18期127-129,共3页China & Foreign Medical Treatment

摘　　要：目的探究在对小儿支气管肺炎患儿进行治疗时应用常规方案联合沐舒坦氧驱动雾化吸入进行治疗的效果,评价不良反应发生状况。方法回顾性分析该院中2016年10月—2017年6月间收入的所有小儿支气管肺炎患儿的一般资料,根据实验要求,抽取出46例患儿纳入该次研究。通过双色球分组法将所有患儿分为两组,红色球为对照组,蓝色球为实验组,每组中录入23例患者。实验组患儿实施沐舒坦氧驱动雾化吸入配合常规方案治疗方案,对照组患儿在治疗时单纯应用常规方案进行治疗。根据两组患儿的肺功能改变情况和不良反应发生率进行对比。结果实验结果显示,实验组患者的治疗总有效率较对照组明显更高,两组患者治疗总有效率差异有统计学意义(χ^2=34.840 0,P=0.000 0)。实验组患儿的不良反应发生率为4.35%,而对照组患儿的不良反应发生率为26.09%,实验结果显示,对照组不良事件发生率更高,组间差异有统计学意义(χ^2=18.313 9,P=0.000 0)。结论将常规方案联合沐舒坦氧驱动雾化吸入治疗方案,应用于小儿支气管肺炎患儿的治疗中,在一定程度上能够改善患儿的肺功能状况,同时不会对患儿造成额外的不良用药反应,具有积极的用药意义,值得推广使用。Objective To investigate the effect of conventional regimen combined with mucosolvan-driven aerosol inhalation in the treatment of children with bronchopneumonia in children, and to evaluate the occurrence of adverse reactions. Methods The general data of all children with bronchopneumonia in children from October 2016 to June 2017 were retrospectively analyzed. According to the experimental requirements, 46 children were included in the study. All children were divided into two groups by two-color ball grouping method, the red ball was the control group, the blue ball was the experimental group, and 23 patients were included in each group. In the experimental group, the mucosulfan-driven aerosol inhalation was combined with the conventional regimen, and the control group was treated with conventional routine treatment. The lung function changes and incidence of adverse reactions were compared between the two groups. Results The results of the experiment showed that the total effective rate of the patients in the experimental group was significantly higher than that in the control group. The total effective rate of the two groups was significantly different (χ^2=34.840 0,P=0.000 0). The incidence of adverse reactions in the experimental group was 4.35%, while the incidence of adverse reactions in the control group was 26.09%. The experimental results showed that the incidence of adverse events was higher in the control group, and the difference between the groups was significant (χ^2=18.313 9,P=0.000 0). Conclusion The conventional regimen combined with mucosolvan-driven aerosol inhalation therapy for the treatment of children with bronchopneumonia can improve the lung function of children to a certain extent without causing additional defects to the child. The drug reaction has positive drug use significance and is worthy of promotion.

关 键 词：小儿支气管肺炎 氧驱动雾化吸入 常规方案 沐舒坦 临床疗效 

分 类 号：R725[医药卫生—儿科]